Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia

Abstract

OBJECTIVES: The pregabalin dose-response for pain, Patient Global Impression of Change (PGIC), and sleep quality measures in painful diabetic peripheral neuropathy (pDPN), postherpetic neuralgia (PHN), and fibromyalgia (FM) is relevant for physicians treating these patients. This analysis aimed to demonstrate the dose-response of pregabalin for each indication and describe the onset (incidence), onset/continuation (prevalence), and resolution of adverse events (AEs) occurring during treatment. METHODS: dose-response model examined the dose-response of pregabalin for pain, PGIC, and sleep quality. Safety assessments included onset and prevalence of common AEs each week, and resolution in the first 2 months of treatment. RESULTS: In all indications, the likelihood of patients experiencing pain relief and improvements in PGIC and sleep quality increased in a dose-dependent manner with increasing doses. In all indications, new incidences of dizziness and somnolence were highest after 1 week of treatment, with few subsequent new reports at a given dose. Prevalence rates decreased steadily after 1 week of treatment. In FM, new onset weight gain emerged 6-8 weeks following treatment; prevalence rates generally increased then remained steady over time. With the exception of weight gain, many AEs resolved in month 1. CONCLUSION: The dose-response of pregabalin for pain, PGIC, and sleep quality was demonstrated, highlighting the benefit of achieving the maximum recommended dose of 300 mg/day for pDPN, 300-600 mg/day for PHN, and 300-450 mg/day for FM. Common AEs are generally seen within 1 week of starting treatment, with few subsequent new reports at a given dose. New onset weight gain occurs after 6 weeks of treatment, reinforcing the need for regular monitoring of weight.

Overview

Integrity signals

Registry

Crossref · 10.1080/00325481.2017.1384691

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 9

  1. Mease PJ, 2008, J Rheumatol, 35, 502
  2. Pfizer Inc. Study 1008-040. Data on file
  3. Pfizer Inc. Study 1008-173. Data on file
  4. Pfizer Inc. Study 1008-030. Data on file
  5. Pfizer Inc. Study 1008-132. Data on file
  6. Gore M, 2010, Am J Manag Care, 16, S144
  7. Sanchez RJ, 2012, Am J Pharm Benefits, 4, 158
  8. Pfizer Inc, 2015, Mu sigma pregabalin dosing by indication and strength
  9. Parsons B, 2015, J Pain Res, 8, 303

Cited by

See all 27

Metadata

Authors
Arnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W.
Affiliations
  • University of Cincinnati (US)
  • University of California San Diego (US)
  • Pfizer (United States) (US)
Corresponding author
Park, Peter W.
Venue
Postgraduate Medicine
Published
2017-10-16
Volume
129
Issue
8
Pages
921-933
ISSN
  • 0032-5481 (ISSN-L)
  • 1941-9260
OpenAlex
W2761247062
Cited by
27
References
38
Citations by year
2026: 5 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 3
FWCI
1.62
Type
journal article
Language
en
Open access
closed
Locations
  • Postgraduate Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
pregabalin, dose-response relationship, diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, analgesia, Patient Global Impression of Change, sleep quality, adverse events, dizziness, sleepiness, weight gain, drug safety
MeSH terms
Pregabalin, Adolescent, Adult, Aged, Aged, 80 and over, Analgesics, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Fibromyalgia, Humans, Male, Middle Aged, Sleep, Neuralgia, Postherpetic, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. https://app.cochat.ai/papers/10.1080/00325481.2017.1384691
The paper
Arnold, L. M., McCarberg, B. H., Clair, A. G., Whalen, E., Thomas, N., Jorga, A., Pauer, L., Vissing, R., & Park, P. W. (2017). Dose-response of pregabalin for diabetic peripheral neuropathy, postherpetic neuralgia, and fibromyalgia. Postgraduate Medicine. https://doi.org/10.1080/00325481.2017.1384691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.